218 related articles for article (PubMed ID: 30041175)
1. Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism.
Gao H; Song Z; Zhao Q; Wu Y; Tang S; Alahdal M; Shen Y; Xing Y; Pan Y; Li J; Zhang Y; Jin L
Cell Physiol Biochem; 2018; 48(3):1112-1122. PubMed ID: 30041175
[TBL] [Abstract][Full Text] [Related]
2. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
3. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
5. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation.
Ma X; Hui H; Liu Z; He G; Hu J; Meng J; Guan L; Luo X
Diabetes Obes Metab; 2009 Oct; 11(10):953-65. PubMed ID: 19531053
[TBL] [Abstract][Full Text] [Related]
6. PGLP-1, a novel long-acting dual-function GLP-1 analog, ameliorates streptozotocin-induced hyperglycemia and inhibits body weight loss.
Gao H; Zhao Q; Song Z; Yang Z; Wu Y; Tang S; Alahdal M; Zhang Y; Jin L
FASEB J; 2017 Aug; 31(8):3527-3539. PubMed ID: 28461341
[TBL] [Abstract][Full Text] [Related]
7. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
8. A mutated glucagon-like peptide-1 with improved glucose-lowering activity in diabetic mice.
Gao M; Tong Y; Gao X; Yao W
J Pharm Pharmacol; 2013 Apr; 65(4):539-46. PubMed ID: 23488782
[TBL] [Abstract][Full Text] [Related]
9. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
10. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
11. Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes.
Skurikhin EG; Stronin OV; Epanchintsev AA; Pershina OV; Ermakova NN; Krupin VA; Pakhomova AV; Vaizova OE; Dygai AM
Bull Exp Biol Med; 2017 Sep; 163(5):635-638. PubMed ID: 28948559
[TBL] [Abstract][Full Text] [Related]
12. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
13. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
[TBL] [Abstract][Full Text] [Related]
15. EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.
Gao H; Zhao Q; Li K; Qin F; Yin X; Lu Z; Song Z; Wu Y; Shen Y; Pan Y; Jin L; Yanfeng Zhang
Exp Cell Res; 2021 Feb; 399(1):112454. PubMed ID: 33359447
[TBL] [Abstract][Full Text] [Related]
16. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
17. Novel Pentapeptide GLP-1 (32-36) Amide Inhibits β-Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice.
Sun L; Dai Y; Wang C; Chu Y; Su X; Yang J; Zhou J; Huang W; Qian H
Chem Biol Drug Des; 2015 Dec; 86(6):1482-90. PubMed ID: 26178446
[TBL] [Abstract][Full Text] [Related]
18. Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1.
Lin LC; Lee LC; Huang C; Chen CT; Song JS; Shiao YJ; Liu HK
Phytomedicine; 2019 Sep; 62():152946. PubMed ID: 31102890
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
20. Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro.
Liu YX; Si MM; Lu W; Zhang LX; Zhou CX; Deng SL; Wu HS
J Ethnopharmacol; 2015 May; 166():168-75. PubMed ID: 25792018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
